Phase II study of clofarabine in pediatric patients with refractory or relapsed acute myeloid leukemia.
暂无分享,去创建一个
R. Arceci | P. Steinherz | P. Gaynon | S. Jeha | S. Goldman | S. Rheingold | B. Razzouk | R. Kadota | L. Bomgaars | K. Stine | L. Steinherz | M. Rytting | L. Luchtman-Jones | E. Albano | A. Altman | K. Ritchey | Edythe A. Albano
[1] P. Steinherz,et al. A Novel Therapy of Clofarabine in Combination with Etoposide and Cyclophosphamide Shows Activity in Pediatric Patients with Refractory or Relapsed Acute Leukemia. , 2007 .
[2] M. McDevitt,et al. A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias. , 2007, Blood.
[3] P. Steinherz,et al. Clofarabine induced durable complete remission in heavily pretreated adolescents with relapsed and refractory leukemia. , 2007, Journal of pediatric hematology/oncology.
[4] G. Gustafsson,et al. Improved outcome after relapse in children with acute myeloid leukaemia , 2007, British journal of haematology.
[5] C. Pui,et al. Prognostic factors and outcome of recurrence in childhood acute myeloid leukemia , 2007, Cancer.
[6] J. Fay,et al. Phase II Study of Clofarabine and Cytosine Arabinoside in Adult Patients with Relapsed AML and in Elderly Patients with Untreated AML Who Are at High Risk of Anthracycline Toxicity. , 2006 .
[7] Z. Estrov,et al. Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older. , 2006, Blood.
[8] R. Arceci,et al. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] V. Gandhi,et al. Biochemical modulation of cytarabine triphosphate by clofarabine , 2005, Cancer Chemotherapy and Pharmacology.
[10] H. Kantarjian,et al. Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. , 2004, Blood.
[11] C. Harrison,et al. MRC trials in childhood acute myeloid leukaemia. , 2004, Annals of hematology.
[12] A. Baruchel,et al. Outcome in children with relapsed acute myeloid leukemia after initial treatment with the French Leucemie Aique Myeloide Enfant (LAME) 89/91 protocol of the French Society of Pediatric Hematology and Immunology. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] H. Kantarjian,et al. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. , 2003, Blood.
[14] R. Arceci,et al. Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group Study 2951. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] S. Hirschfeld,et al. Regulatory approvals of pediatric oncology drugs: previous experience and new initiatives. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] F. Khuri,et al. Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] S. Eriksson,et al. Down-regulation of deoxycytidine kinase in human leukemic cell lines resistant to cladribine and clofarabine and increased ribonucleotide reductase activity contributes to fludarabine resistance. , 2003, Biochemical pharmacology.
[18] Y. Ravindranath. Recent advances in pediatric acute lymphoblastic and myeloid leukemia , 2003, Current opinion in oncology.
[19] R. Arceci. Progress and controversies in the treatment of pediatric acute myelogenous leukemia , 2002, Current opinion in hematology.
[20] W. Plunkett,et al. DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[21] W. Plunkett,et al. Purine and pyrimidine nucleoside analogs. , 2001, Cancer chemotherapy and biological response modifiers.
[22] A. Oakhill,et al. FLAG (fludarabine, high-dose cytarabine, and G-CSF) for refractory and high-risk relapsed acute leukemia in children. , 1999, Medical and pediatric oncology.
[23] L. Hertel,et al. Comparison of the mechanism of cytotoxicity of 2-chloro-9-(2-deoxy-2- fluoro-beta-D-arabinofuranosyl)adenine, 2-chloro-9-(2-deoxy-2-fluoro- beta-D-ribofuranosyl)adenine, and 2-chloro-9-(2-deoxy-2,2-difluoro- beta-D-ribofuranosyl)adenine in CEM cells. , 1999, Molecular pharmacology.
[24] K. Wheatley,et al. Outcome for children with relapsed acute myeloid leukaemia following initial therapy in the Medical Research Council (MRC) AML 10 trial , 1999, Leukemia.
[25] K Wheatley,et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. , 1998, Blood.
[26] J. Boos,et al. Duration of first remission predicts remission rates and long-term survival in children with relapsed acute myelogenous leukemia , 1998, Leukemia.
[27] R. Gray,et al. Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukaemia: results of the United Kingdom Medical Research Council's 10th AML trial , 1998 .
[28] J. Kersey. Fifty years of studies of the biology and therapy of childhood leukemia. , 1997, Blood.
[29] C. Pui. Childhood Leukemias: Acute lymphoblastic leukemia , 2006 .
[30] B. Cheson,et al. Neurotoxicity of purine analogs: a review. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] C. Bloomfield,et al. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .